Pursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Directors of Amerise Biosciences Ltd approved the unaudited financial results for the quarter ended June 30, 2025, at a meeting held on July 24, 2025. Revenue from operations stood at Rs 6.37 lacs, down from Rs 18.80 lacs in the previous quarter (Q4 FY25). Total expenses were Rs 7.18 lacs, leading to a loss before tax of Rs 0.81 lacs and a net loss of Rs 0.81 lacs (EPS: Rs 0.00). The statutory auditor BIPIN & Co. issued an unqualified limited review report. The company continues to operate in a single segment with paid-up equity capital of Rs 660.69 lacs and negative other equity of Rs 122.71 lacs (as on March 31, 2025), indicating accumulated losses.
The company posted a net loss in Q1 FY26 with significantly lower revenue compared to the prior quarter, suggesting weak business activity and possible stress on operations. Shareholders should note the negative other equity position, which indicates past accumulated losses have eroded reserves, raising concerns about long-term financial stability despite the clean auditor review.